Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature,... Read More

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature,... Read More

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80 th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register... Read More

ALAMEDA, Calif. / Mar 24, 2025 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive... Read More

Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic®/Wegovy® Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025 ALAMEDA, Calif. / Mar 13, 2025 / Business Wire /... Read More

Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second Sight Medical Products, Cortigent achieved the first and only FDA authorization (under a Humanitarian Device Exemption) for an... Read More

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative... Read More

ALAMEDA, Calif. / Dec 04, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December... Read More

Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Announces $5M equity financing which secures solid financial position into... Read More

ALAMEDA, Calif. / Oct 22, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference,... Read More

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice-yearly administration Study will represent the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Sep 26, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani”... Read More

ALAMEDA, Calif. / Sep 23, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive... Read More

Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously announced sham-implant adjusted preclinical weight loss of 20%, which is comparable to the weight loss produced from the... Read More

ALAMEDA, Calif. / Aug 28, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26 th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York. Vivani’s Chief Executive Officer, Adam... Read More

Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniature, subdermal GLP-1 (exenatide) implant in obese or overweight patients FDA provided clearance of the Investigational New Drug Application for NPM-119, providing further confidence to advance the Company’s emerging portfolio of GLP-1 implants into clinical phase development Solid financial... Read More

Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support the development of Vivani’s miniature, 6-month GLP-1 (exenatide) NanoPortal™ implant for chronic weight management in obese or overweight patients ALAMEDA, Calif. / Jul 11, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq:... Read More

NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications, by providing long-term therapeutic delivery of exenatide for six months Study will represent first clinical application of NanoPortal™, the company’s proprietary, implant platform technology ALAMEDA, Calif. / Jun 13, 2024 / Business Wire / Vivani Medical,... Read More

Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight Felines share many pathophysiologic obesity phenotypes with humans, further supporting clinical evaluations of miniature, subdermal GLP-1 implants for obesity reduction Development partner, Okava Pharmaceuticals, is studying OKV-119 for the treatment of pre-diabetes, diabetes, and obesity in companion felines ALAMEDA, Calif.... Read More

Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients, type 2 diabetes, and other chronic diseases Stable financial position supports operations into the second half of 2025 and potential delivery of key portfolio milestones ALAMEDA, Calif. / May 13, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani”... Read More

ALAMEDA, Calif. / May 09, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today announced that it will present at the TIDES Conference 2024 at 4:30 p.m. ET at the Hynes Convention... Read More

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenatide implant) preclinical weight loss data comparable to semaglutide, active ingredient in Ozempic ® /Wegovy ® $15 million financing round enables acceleration of priority development programs and secures operations into the second half of 2025 ALAMEDA, Calif. / Mar 26, 2024 /... Read More

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, with partner Alkermes, secured in 2012 approval of Bydureon® (exenatide injection), the world’s first once-weekly GLP-1 receptor agonist, a class of drugs that now includes blockbusters Ozempic®, Trulicity®, and Wegovy® ALAMEDA,... Read More

ALAMEDA, Calif. / Mar 01, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced that it has entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares of common stock and warrants to purchase up to an aggregate of 3,947,368 shares... Read More

NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active pharmaceutical ingredient in NPM-139, with the added potential benefit of once-yearly dosing NPM-115 and... Read More

Company announces addition of NPM-115 (high-dose exenatide implant) to its emerging pipeline, a potential alternative to life-long injections or pills for long-term GLP-1 therapy for the treatment of chronic weight management in obese or overweight patients Vivani is actively engaged in discussions with the US FDA to enable the expeditious initiation of LIBERATE-1, proposed FIH study of NPM-119 in patients with type 2... Read More

ALAMEDA, Calif. / Oct 16, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton San Francisco Union Square on October 18, 2023. Vivani President and Chief Executive Officer Adam Mendelsohn,... Read More

ALAMEDA, Calif. / Sep 07, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at the Napa Valley Marriott Hotel and Spa in Napa, California on September 19, 2023. Dr. Adam Mendelsohn,... Read More

EMERYVILLE, Calif. / Sep 05, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering targeted neurostimulation technology to recover critical body functions, will present the Early Feasibility Study (EFS) results for the Orion ® Visual... Read More

EMERYVILLE, Calif. / Aug 14, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the second quarter of 2023 and provided a business update. Vivani™ continues to advance its emerging portfolio of innovative, highly differentiated drug implants leveraging... Read More

EMERYVILLE, Calif. / Jul 11, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering neurostimulation to recover critical body function, has completed the fifth year of its Early Feasibility Study (EFS) of... Read More

EMERYVILLE, Calif. / Jun 14, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-term therapeutic implants, announced today that Company CEO Adam Mendelsohn, Ph.D. has been invited to participate at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.... Read More

EMERYVILLE, Calif. / May 15, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product NPM-119 for the treatment of patients with type 2 diabetes and/or obesity, today reported financial results for the first quarter and provided a business update. NPM-119 is a preclinical stage, 6-month, GLP-1... Read More

EMERYVILLE, Calif. / Apr 04, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an emerging biopharmaceutical company which develops miniaturized, subdermal implants today announced that the Company received notice from the National Institutes of Health (“NIH”) of approval of the year 5 funding for the Early Feasibility Clinical Study of the Orion Visual Cortical Prosthesis being... Read More

EMERYVILLE, Calif. / Mar 31, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. According to... Read More

EMERYVILLE, Calif. / Mar 21, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, today announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) for the proposed initial public offering of Cortigent, Inc. (“Cortigent”).... Read More